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Standard assessments for ﬁbromyalgia (FM) diagnosis and core FM symptom domains are needed for biomarker development
and treatment trials. Diagnostic and symptom assessments are reviewed and recommendations are made for standards.
Recommendations for existing assessments include the American College of Rheumatology FM classiﬁcation criteria using the
manualtenderpointSurveyfordiagnosis,thebriefpaininventoryaveragepainvisualanaloguescaleforpainintensity,thefunction
subscaleoftherevisedﬁbromyalgiaimpactquestionnaire(FIQR)forphysicalfunction,thepatientglobalimpressionofchangeand
FIQR for overall/global improvement, the hospital anxiety and depression scale depression subscale for depression, the multiple
ability self-report questionnaire for cognitive dysfunction, the fatigue severity scale for fatigue, the FIQR for multidimensional
function/health-related quality of life, the jenkins sleep scale for sleep disturbance, and the ﬁbromyalgia intensity score for
tenderness. Forthcoming assessments including the FIQR for diagnosis, NIH PROMIS, and FIBRO Change scales are discussed.
1.Introduction
Fibromyalgia (FM) is one of the most challenging disorders
to manage. Treatment advances are needed to improve the
care of FM patients. FM is currently a very subjective dis-
order, and the development of biomarkers could improve
care by simplifying FM diagnosis and objectively quantifying
symptom severity. Numerous FM biomarkers have been
proposed [1]. However, a recent review characterized the
current state of FM biomarker development as an “abyss”
[1]. Biomarker development has been limited by the lack
of universal, “gold standard” deﬁnitions for FM clinical
diagnosis and symptom severity against which biomarkers
can be compared. Similarly, a standard set of assessments
for all core FM symptom domains is needed for inclusion
in treatment trials to develop better therapies and improve
the ability to make eﬃcacy comparisons between treatments.
Unfortunately, consensus on standard assessments in re-
search to quantify the severity of FM symptoms is lacking,
and recommendations for standard assessments have not
been made previously. This paper represents one author’s
review of the available literature and his recommendations
for current and future assessments to clinically diagnose FM
and measure the severity of FM symptoms in research to
enable development of new therapies and biomarkers. The
recommendations made in this paper are intended to be a
starting point for discussions in a group such as outcome
measures in rheumatology (OMERACT) rather than the
ﬁnal articulation of standards to be used. While none of the
assessments discussed herein are perfect, consensus within
the FM research community must be reached if timely ad-
vances for improving patient care are to be made.
2. Recommended FM Clinical
DiagnosticCriteria
FM is a very complex disorder. In addition to widespread
pain and tenderness, FM patients also typically suﬀer from2 Pain Research and Treatment
numerous other symptoms that can include, but are not lim-
ited to, fatigue, cognitive dysfunction (ﬁbrofog), disturbed
(nonrestorative) sleep, depression, anxiety, stiﬀness, ten-
derness and functional disability [2]. The number and sever-
ity of associated symptoms varies from patient-to-patient,
making development of uniﬁed diagnostic criteria diﬃcult.
While not originally intended for clinical diagnosis, the
American College of Rheumatology (ACR) FM classiﬁcation
criteria have been used in the clinic to identify FM patients
since their publication in 1990 [3]. These criteria include
the presence of widespread pain for at least 3 months and
pain upon palpation of at least 11 of 18 tender points with
4kg/cm 2 of force. However, performance of the classiﬁcation
criteria in clinical diagnosis is poor, failing to identify almost
half of FM patients [4].
New ACR FM diagnostic criteria have been proposed to
simplify clinical diagnosis by doing away with the need for
performing the tender point examination. The new criteria
diagnose FM by evaluating the distribution of body pain in
combination with symptom severity [5]. While these new
criteria have been provisionally accepted by the ACR, ﬁnal
acceptance is awaiting validation studies. However, these
new criteria have been criticized for their lack of precision
or mechanistic features and complete symptom focus [6–
8]. Also, diagnosis via the new criteria is based on a
physician’s subjective assessment of the extent and severity
of the patient’s somatic symptoms [9]. Therefore, FM
diagnosis using the new criteria is likely to diﬀer from one
physician to another. Due to these issues, the new diagnostic
criteria cannot be recommended until validation studies are
completed.
Though not perfect, the 1990 ACR classiﬁcation criteria
has been used to identify FM patients for inclusion in clinical
trials for the past 20 years, and broad consensus exists for
its use. At least part of the poor performance of the 1990
ACR criteria in clinical diagnosis is likely due to nonstandard
performance of the tender point examination. Performance
of the tender point exam can be improved by using the
manual tender point Survey (MTPS) method [10]. The
MTPS has been shown to reduce variability in performance
of the tender point exam and identify FM patients with
high sensitivity and speciﬁcity [10]. The MTPS consists of
standardized components including (1) location of the ten-
der point sites, (2) patient and examiner positioning, (3)
order of tender point examination, (4) pressure application
technique, and (5) pain severity rating scores in which FM
patients rate pain severity upon digital palpation of each
tender point on a verbal 11-point numerical rating scale
(NRS) from 0 (no pain) to 10 (worst pain), with a pain
severity score of at least 2 required to count a tender point as
positive. Until the new FM diagnostic criteria are validated,
the 1990 ACR ﬁbromyalgia classiﬁcation criteria utilizing the
MTPS are recommended for the diagnosis of FM patients in
research studies (Table 1).
3. Recommended FM Core Symptom Domains
As previously discussed, FM is a complex disorder with
numerous symptoms occurring along with widespread pain
and tenderness [2]. Since eﬀective FM management requires
a treatment regimen that addresses not only pain but all
associated FM symptoms [11], multiple biomarkers will
likely be necessary to evaluate all FM symptom domains.
While phase-three FM treatment trials have evaluated mul-
tiple symptom domains (Table 2), the symptoms assessed
across trials have been inconsistent. This is likely because
the US Food and Drug Administration (FDA) has made the
improvement of pain the primary consideration for approval
of FM medications, and a required core set of symptom
domains for evaluation in FM treatment trials does not
exist. Discrepancies in symptoms assessed by treatment trials
can lead to bias, since researchers tend to only evaluate
symptoms likely to be improved by the treatment under in-
vestigation and ignore symptoms likely to be made worse. A
required core set of symptom domains are needed so that a
comprehensive set of FM biomarkers can be developed and
bias in treatment trials can be reduced.
Recommendations for a core set of FM symptom do-
mains to be assessed in treatment trials have been made
previously (Table 1)[ 12] .T h e s er e c o m m e n d a t i o n sa r o s e
from a Delphi exercise of FM patients and expert clinicians
to determine symptoms that should be evaluated in all
treatment trials [2]. While it may be advisable for additional
symptoms to be evaluated in some circumstances (e.g.,
anxiety for an antidepressant trial), a core set of 9 symptom
domains were recommended for assessment including pain
intensity, physical function, patient global impression of
change, cognitive dysfunction (ﬁbrofog), fatigue, multidi-
mensional function/health-related quality of life (HRQoL),
sleep disturbance, tenderness and depression (Table 1). Since
consensus for these core domains exists, it is recommended
that biomarkers be developed to evaluate these 9 symptom
domains.
4. No Recommended Assessments for FM Core
Symptom Domains CurrentlyExist
While recommendations for core symptom domains exist,
there are no accepted standards for assessments to evaluate
these domains. Standard measures are needed against which
biomarkers can be compared for development and to allow
direct comparisons between treatment trial results. Pub-
lished work to develop a consensus set of FM outcome meas-
ures has been limited to two papers [13, 14]. The work
by Choy et al. pooled data from 10 ﬁbromyalgia treatment
trials to determine the construct validity of questionnaires
that have been used to assess change in a number of FM
symptom domains including pain, patient global, fatigue,
multidimensional function (which included HRQoL), sleep,
depression, physical function, tenderness, ﬁbrofog, anxiety,
and stiﬀness [13]. The authors did not compare question-
naires to one another, and no speciﬁc recommendations for
assessments were made. Instead, pooled psychometric prop-
erties of questionnaires for each symptom domain were
assessed. Support was found for construct validity of self-
report questionnaires for pain, fatigue, depression, physical
function, and multidimensional function. However, supportPain Research and Treatment 3
Table 1: Recommended assessments for ﬁbromyalgia diagnosis and core symptom domains.
Symptom domain Assessment
Diagnosis 1990 ACR ﬁbromyalgia classiﬁcation criteria utilizing the MTPS
Pain intensity NRS from question 5 of the BPI
Physical functioning FIQR physical functioning subscale




Multidimensional function/health-related quality of life FIQR
Sleep disturbance JSS
Tenderness MTPS-FIS
ACR: american college of rheumatology, BPI: brief pain inventory, FIQR: revised ﬁbromyalgia impact questionnaire, FIS: ﬁbromyalgia intensity score, FSS:
fatigue severity scale, HADS-D: depression subscale of hospital anxiety and depression scale, JSS: jenkins sleep scale, MASQ: multiple abilities self-report
questionnaire, MTPS: manual tender point survey, NRS: numeric rating scale, PGIC: patient global impression of change.
Table 2: Assessments used to evaluate ﬁbromyalgia symptom severity in medication trials.
Symptom Medication used in treatment trials
Pregabalin Duloxetine Milnacipran Sodium oxybate
Fatigue MAF MFI MFI Fatigue VAS
Fibrofog —— M A S Q —
Sleep MOS-Sleep — JSS, MOS-sleep FOSQ, JSS
Depression BDI, HADS-D BDI-II, HAMD17 BDI —
Anxiety HADS-A Beck Anxiety Inv. Beck anxiety inv. —
Pain Pain VAS, Pain NRS BPI-mod short form Pain VAS, McGill pain quest. Pain VAS
Physical disability FIQ, F-HAQ FIQ, SDS FIQ, MDHAQ FIQ
Global/QOL FIQ, CGI-C, PGI-C, SF-36 EQ-5D, FIQ, CGI-S,
PGI-I, SF-36 FIQ, PGI-C, SF-36 FIQ, CGI-C, CGI-S,
PGI-C, SF-36
Tenderness MTPS-FIS — — TPI
BDI: beck depression inventory, BPI: brief pain inventory, CGI-C: clinician global impression of change, CGI-S: clinician global impression of severity, EQ-
5D: EUROQOL 5-D qUESTIONNAIRE, F-HAQ: ﬁbromyalgia health assessment questionnaire, FIQ: ﬁbromyalgia impact questionnaire, FIS: ﬁbromyalgia
intensity scale, FOSQ: Functional outcomes of sleep questionnaire, HADS: hospital anxiety and depression scale (-D denotes depression subscale, -Ad e n o t e s
anxiety subscale), HAMD17: 17-item hamilton rating scale for depression, Inv.: inventory, JSS: jenkins sleep scale, MAF: multidimensional assessment of
fatigue, MASQ: multiple abilities self-report questionnaire, MDHAQ: multi-dimensional health assessment questionnaire, MFI: multidimensionalf a t i g u e
inventory,MOS-sleep: medicaloutcomes studies sleep scale, MTPS: manual tender point survey, NRS: numericrating scale, PGI-C: patientglobal impression
of change, PGI-I: patient global impression of improvement, QOL: quality of life, QUEST.: questionnaire, SDS: sheehan disability scale, SF-36: short form
health survey, TPI: tender point index, VAS: visual analogue scale.
was not found for use of full-length sleep questionnaires
(including the medical outcomes studies (MOS) sleep scale).
The lack of support for sleep questionnaires was because
many items assessed sleep problems such as snoring and
shortnessofbreaththatarenotrelevanttomostFMpatients.
Theauthorsrecommendedeitherusingthesleepdisturbance
subscale of the MOS sleep scale in isolation or developing
a new FM-speciﬁc sleep questionnaire for use in clinical
trials. Validity could also not be determined for ﬁbrofog,
anxiety, or stiﬀness assessments because these domains were
measured by only one instrument in the trials (the multiple
abilities self-report questionnaire (MASQ), anxiety subscale
of the hospital anxiety and depression scale (HADS), and
stiﬀness subscale of the ﬁbromyalgia impact questionnaire
(FIQ), resp.).
T h ew o r kb yC a r v i l l ea n dC h o yr e v i e w e d1 8 5F Mt r i a l s
to identify assessment instruments for core FM domains
that were sensitive to change for both pharmacologic
and nonpharmacologic treatments [14]. The authors only
compared the 5 assessments that were most often used
for each core symptom domain, signiﬁcantly limiting the
questionnaires that were evaluated since concordance of
assessments across trials was low. Across all domains includ-
ing pain, patient global, fatigue, sleep, and anxiety, visual
analogue scales (VASs) were found to be sensitive to change.
For pain, the FIQ, tender point count, and pressure point
threshold were insensitive to change. While evaluation of
depression questionnaires was limited due to the use of
multiple different assessments across trials and the exclusion
of patients with signiﬁcant depression from many trials, the
Hamilton and Center for Epidemiologic Studies Depression
scales were found to be more sensitive to change than
the Beck depression inventory (BDI). All anxiety scales
analyzed were insensitive to change in pharmacologic trials4 Pain Research and Treatment
includingtheBeckanxietyinventory,statetraitanxietyindex
(STAI) and the FIQ anxiety subscale. For fatigue, Likert
scales showed good sensitivity, but the FIQ fatigue subscale
did not. For health-related quality of life, the physical
component of the short form36 was sensitive to change in
pharmacologic studies, but the mental component score was
not. For sleep, the FIQ sleep item was sensitive to change
in nonpharmacologic trials but not in pharmacologic trials.
For evaluation of multidimensional function, the global FIQ
score was moderately sensitive to change in both pharma-
cologic and nonpharmacologic trials. While the analyses in
this work are instructive, no speciﬁc recommendations for
assessment measures were made.
5. Recommended PainIntensityAssessment
The initiative on methods, measurement, and pain assess-
ment in clinical trials (IMMPACT) has provided recom-
mendations for questionnaires to be used in interpreting
the clinical importance of therapeutic outcomes in clinical
trials of chronic pain treatments that may be applicable to
FM [15]. IMMPACT recommends assessment of four core
chronic pain outcome domains including (1) pain intensity,
(2) physical functioning, (3) emotional functioning, and (4)
participant ratings of overall improvement. A 0 to 10 NRS
was recommended to assess pain intensity, but no speciﬁc
recommendations for the wording of instructions or anchors
oftheNRSweremade.ToensureuniformityacrossFMtrials,
IrecommendwordingfromtheaveragepainNRSofthebrief
pain inventory (BPI) to be used which asks “please rate your
painbycircling theonenumber thatbestdescribes yourpain
on average” and has anchors that vary from “no pain” to
“pain as bad as you can imagine” since this wording can help
limit recall bias and reduce ceiling eﬀects commonly seen in
FM patient trials [16].
6.Recommended Physical
FunctioningAssessment
IMMPACT recommends the multidimensional pain inven-
tory (MPI) [17] and the interference scale of the (BPI)
[16] for assessment of physical functioning unless a well-
validated disease-speciﬁc measure is available. Since the FIQ
physical functioning subscale is a well-validated FM-speciﬁc
measure that has been used to assess physical functioning in
all FM clinical trials (Table 2)[ 18], it is reasonable to use
it to assess physical functioning. However, the FIQ physical
functioning subscale has been criticized for its gender
bias, nonlinearity, nonunidimensionality, and systematic
underestimation of functional impairment by inclusion of
infrequently performed activities [19]. The FIQ was recently
revised as the FIQR to address some of these criticisms
and allow for computerized administration [20]. Therefore,
the FIQR physical functioning subscale is recommended for
assessment of physical function in FM patients.
7. Recommended Overall/Global
Improvement Assessments
The patient global impression of change scale (PGIC) is
IMMPACT recommended for evaluating participant ratings
of overall improvement in pain treatment trials [15]. The
PGIC uses a 7-point Likert scale that varies from 1 “very
much improved” to 7 “very much worse” to quantify patient
global response to treatment [21]. The PGIC is a standard
assessment in clinical trials, and various forms of the PGIC
have been used in all FM treatment trials (Table 2). A speciﬁc
form of the PGIC has been linguistically validated into
12 languages to allow for use in FM research worldwide
[22], and this form of the PGIC is recommended to assess
overall/global improvement in combination with the FIQR
(Table 1).
8. Recommended Depression Assessment
The beck depression inventory (BDI) is the IMMPACT rec-
ommended depression assessment for pain treatment trials
[15]. The BDI was recommended based on its excellent psy-
chometric properties, extensive use in pain clinical research,
and responsiveness to change in pain clinical trials. The BDI
consistsof21multiplechoiceitems,witheachitemanswered
by choosing which of four statements best describes the way
the patient feels [23]. The BDI was designed to assess the
severity of current depressive symptoms, with scores ranging
from 0 to 63 with higher scores indicating more severe
depression. The original BDI evaluated symptoms over the
pastweek,butthistimeframewasincreasedtotwoweeksfor
the current version of the BDI, the BDI-II, for consistency
with Diagnostic and Statistical Manual on Mental Disorders
(DSM-IV) criteria for major depressive disorder [24]. The
BDI-II was also modiﬁed to include assessments for all nine
DSM-IV criteria (the original BDI only met six of the nine
criteria). The BDI-II has been linguistically validated into 12
languages for use in international FM treatment trials [22].
Normative data on the BDI and BDI-II are available.
While the BDI is recommended for use in pain treatment
trials and has been used in FM trials (Table 2), it is not
recommended to quantify depression severity in FM patients
duetoitslackofunidimensionality.TheBDIdoesnotspecify
patients answer on the basis of their depressive symptoms
but to comment on how they “...have been feeling.” Only
one of the 21 BDI-II items speciﬁcally addresses feelings
of sadness, the rest of the items query general physical
and mental concepts not speciﬁc for depression including
tiredness/fatigue, concentration diﬃculty, sleep changes, and
loss of energy. Given the myriad of coexisting FM symptoms,
it is likely the BDI functions as more of a general measure
of symptomatology in FM patients rather than a speciﬁc
measure of depression symptom severity. This view is sup-
ported by a study comparing the BDI to a computerized
diagnostic interview schedule (C-DIS) for diagnosing major
depressive disorder (MDD) in FM patients [25]. The C-DIS
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[26, 27]. This study found that while the C-DIS detected
MDD in 22% of FM patients, the BDI estimate was much
higher at 55%. The authors felt that the BDI overestimated
the presence of MDD because numerous BDI items evaluate
nondepressive symptoms that are part of the FM syndrome
process and that the BDI lacked utility as a unidimensional
measure of depression in FM patients. Factor analyses of
the BDI have identiﬁed three dimensions, including negative
attitudes toward self (also termed general depression),
performance impairment and somatic concerns [28, 29].
The BDI-II has also been shown to be multidimensional,
composed of two ﬁrst-order factors representing cognitive
and noncognitive symptoms [24, 30]. It is very important
that assessments used in treatment trials and to develop
biomarkers be unidimensional to ensure speciﬁcity. Given
the lack of speciﬁcity of the BDI for assessing depression
symptoms, it cannot be recommended to quantify depres-
sion severity in FM trials.
The HADS depression subscale has been used previously
to evaluate change in depressive symptoms in FM treatment
trials (Table 2). The HADS was originally developed to
quantify the severity of anxiety and depressive symptoms
in nonpsychiatric hospital clinic patients [31]. To pre-
vent somatic disorders common in these patients from
falsely affecting scores, symptoms of anxiety and depression
that relate to physical disorders were excluded to ensure
unidimensionality of the anxiety and depression subscales
that have been conﬁrmed by factor analysis in multiple
populations [32]. The HADS includes 7 items each to assess
anxiety and depressive symptoms (the HADS-A and HADS-
D, resp.), with each item answered on a four-point (0 to
3) scale so that possible scores range from 0 to 21 for
both anxiety and depressive symptoms with higher scores
indicating more severe symptoms. The HADS has been
translated into a number of languages allowing for its use in
international trials.
While the HADS-D has not been speciﬁcally validated
in FM patients, its validity to quantify depression symptoms
has been shown in a variety of patient populations including
somatic, psychiatric, and primary care patients and in the
general population [32]. The HADS-D also has proven
validity in its ability to reﬂect change in depression severity
in treatment trials [33]. An analysis of data from three
pregabalin FM trials supports diagnostic validity of the
HADS by showing that, using a standard cutoﬀ score of
≥11 on the HADS-D to identify patients with MDD, 27%
of enrolled patients in the trials had MDD, a percentage
consistent with previously reported MDD rates in FM
patientswhengold-standarddiagnosticassessmentsaredone
[34]. Similarly, 38% of patients in the FM pregabalin trials
were found to have an anxiety disorder using the HADS-
A, consistent with previously published rates in FM patients
[34, 35]. Based on this, the HADS-D is recommended for
assessment of depressive symptoms in FM patients (Table 1).
9. CognitiveDysfunctionAssessments
Core FM domains that lack published recommendations
for self-report questionnaires include cognitive dysfunction,
fatigue, multidimensional function/HRQoL, sleep, and ten-
derness. While numerous assessments exist for each domain
in the literature, most were developed for use in patient
populationsotherthanFM.Thisissigniﬁcant,sinceconcepts
and psychometric properties of a measure may not hold
across patient populations. While cognitive dysfunction is
a signiﬁcant problem for many FM patients, assessment
in large clinical trials has been hindered by the time and
expertise required to perform the complex neurocognitive
tests that can quantify cognitive dysfunction in FM [36]. The
multiple ability self-reportquestionnaire (MASQ)is the only
self-report questionnaire that has been used in FM clinical
trials to assess cognitive dysfunction [37]. The MASQ is a
self-report measure comprising items to assess ﬁve cognitive
domains including language, visuoperception, verbal mem-
ory, visual memory, and attention. While originally written
in English, the MASQ has been translated and linguistically
validated into 12 diﬀerent languages to facilitate its use in
international FM studies [22]. For this reason, the MASQ
is recommended for assessment of cognitive dysfunction in
ﬁbromyalgia trials. However, it is hoped that computerized
batteries of neurocognitive tests will soon become available
to provide more objective measures of cognitive function
for use in clinical trials [36] since self-assessment is poorly
correlated with objective measures of cognitive function
and has poor discriminating ability for patients with mild
cognitive impairment [38].
10. FatigueAssessments
Numerous self-report questionnaires have been used to
assess fatigue severity in FM treatment trials including the
multidimensional fatigue index (MFI) [39], the multi-
dimensional assessment of fatigue (MAF) [40], and the
fatigue severity scale (FSS) [41] .W h i l en o n eo ft h ef a t i g u e
questionnaires were developed in FM patients, the MFI was
developed in chronic fatigue syndrome patients who have
fatigue symptoms similar to those seen in FM. The MAF
was developed in rheumatoid arthritis patients, while the
FSS was developed in patients with multiple sclerosis and
systemiclupuserythematosus.Allthreescalesareavailablein
numerous languages, allowing for their use in international
FM studies.
The MFI is a 20-item scale that covers 5 dimensions:
general fatigue, physical fatigue, mental fatigue, reduced
motivation and reduced activity. Four items in each subscale
are answered on a 5-point Likert scale with item scores
summed to yield subscale scores and a total score that varies
between 20 and 100 with higher scores indicating more
severe fatigue symptoms. The MFI is reliable and valid in
FM patients [42], and it has been linguistically validated
into 12 languages to enable use in international FM studies
[22]. Normative data for the MFI is available for multiple
subgroups including the general population [43].
The MAF is a 16-item scale (14, 10-point NRSs and
2, 4-point Likert scales) that measures 4 dimensions of
self-reported fatigue: severity (2 items), distress (1 item),
timing (2 items; how often fatigue occurs and change in6 Pain Research and Treatment
fatigue over the past week), and degree of interference
with activities of daily living (11 items including household
chores, cooking, bathing, dressing, working, socializing, sex,
leisure, shopping/errands, walking, and exercise other than
walking) [40]. The global fatigue index (GFI), a measure
of global fatigue severity derived from 15 of the MAF
items, has a scoring range that varies from 7.5 to 50
with higher scores indicating more severe fatigue. While
the GFI technically varies from 1 to 50, patients can only
score a 1 if they have no fatigue; the lowest possible
score for a patient with fatigue is 7.5. The MAF and a
user’s guide are freely available from the developer’s website
(http://www.son.washington.edu/research/maf/). The MAF
i sa v a i l a b l ei n2 5d i ﬀerent language versions for various
regions of the world, allowing for use in international re-
search. While no published validation studies of the MAF in
FM patients exist, a study of the MAF in 663 FM patients
presented at EULAR in 2002 supports use of the MAF in the
assessment of FM patients [44].
The FSS is a 9-item unidimensional measure of fatigue
that is the most often used fatigue-speciﬁc scale in chronic
diseases [41, 45]. The FSS measures fatigue by quantifying
the impact of fatigue on speciﬁc types of functioning rather
than the intensity of fatigue-related symptoms [46]. Each
item is scored on a 7-point NRS, and the FSS score is derived
by averaging all items to yield a score from 1 to 7 with higher
scores indicating more severe fatigue symptoms. The FSS
is freely available in English from the original paper [41]
and has been translated into multiple languages. Validity and
reliability of the FSS in FM patients has been demonstrated
[47].
While all 3 scales were designed to measure fatigue
symptoms, they diﬀer considerably in their composition
and foci. While the MFI is the most comprehensive of
the 3 fatigue scales, questions have been raised about its
dimensional structure, and it appears that MFI may only
discriminate between two fatigue dimensions [48]. Also,
the MFI does not specify patients’ answer on the basis
of their fatigue symptoms but to comment on how they
“...have been feeling lately.” Only two of the 20 MFI items
speciﬁcally address feelings of tiredness, the rest of the items
query general physical and mental concepts not speciﬁc to
fatigue.GiventhemyriadofFMsymptomsthatcontributeto
physical and mental disability, it is likely that the MFI func-
tions as more of a general symptom measure than a speciﬁc
measure of fatigue in FM patients. On the basis of these
limitations, the MFI cannot be recommended to quantify
fatigue severity in FM patients.
In contrast to the MFI, both the MAF and the FSS
instruct patients to answer questions based on their fatigue
symptoms,andeveryquestionspeciﬁcallyasksaboutfatigue,
making the MAF and FSS more speciﬁc fatigue measures
than the MFI. The MAF and FSS have both been recom-
mended for the measurement of fatigue in chronic illnesses
based on their good psychometric properties and demon-
strated ability to detect change over time [49]. However,
a comparison of fatigue measures concluded that the FSS
had the most robust psychometric properties of 19 reviewed
fatigue measures, including both the MAF and the MFI, and
had the best ability to act as an outcome measure sensitive to
change with treatment [49].
The FSS is the recommended fatigue severity measure in
multiple disorders with associated fatigue including systemic
lupus erythematosus [50] and Parkinson’s disease [51]. The
FSS is also easier to score than the MFA and is shorter. For
this reason, the FSS is the recommended fatigue assessment
for use in FM patients.
11. MultidimensionalFunction/HRQoL
Assessments
The FIQ is recommended as a primary eﬃcacy endpoint
measure in FM clinical trials [52] and is the standard
assessment measure for multidimensional function/HRQoL
in FM patients, having been cited in over 300 papers and
translated into 14 languages. The FIQ is a 20-item self-report
questionnaire that quantiﬁes global FM disease severity
by measuring the degree to which FM interferes with a
patient’s life over the past week [18]. The FIQ is divided
into 11 items to assess physical function, 2 “day-of-the-
week” items to quantify the number of days patients “felt
good” or “missed work,” and 7 VASs to assess symptoms of
fatigue, sleep quality, depression, anxiety, stiﬀness, pain, and
work disability. The FIQ has been translated into numerous
languages enabling its use internationally [22].
While the FIQ is universally used in FM trials, problems
with the questionnaire exist. FIQ scoring is complex. The 11
physical function items are each scored on a 4-point Likert
scale ranging from “always” (score of 0) to “never” (score
of 3). Scores on the physical function items are summed,
divided by the number of questions answered, and then
multiplied by 3.33 to yield a 0-to-10 composite physical
function score. The “felt good” “day-of-the-week” item is
reverse scored (to obtain the number of days patients felt
bad), and the result is multiplied by 1.43 to yield a 0-to-10
score. The “missed work” “day-of-the-week” item is derived
by multiplying the number of days by 1.43 to yield a 0-to-
10 score. The VASs are scored by measuring the distance
from the beginning of the line to the patient’s mark in
centimeters. FIQ global scores are derived by summing the
0-to-10 composite physical function, “day-of-the-week,” and
VAS item scores to yield a 0-to-100 score with higher scores
indicating moresevereFM.Inordertomaintainamaximum
possible score of 100, an “equalization calculation” is used
if patients did not answer all 10 sections by multiplying
the global score by 10 and dividing by the number of
sections answered. Content problems in the FIQ have also
been raised [20]. The physical function items were origi-
nally intended for women living in aﬄuent countries and
assumed possession of an automobile, vacuum cleaner, and
washing machine. Also, questions now considered relevant
to FM symptomatology including cognitive dysfunction,
tenderness, balance problems, and environmental sensitivity
were not included in the original FIQ. Finally, the original
FIQ was developed as a pen-and-paper questionnaire and is
incompatible with computer administration.Pain Research and Treatment 7
To address shortcomings of the original FIQ, the authors
have published a revised FIQ, the FIQR [20]. The FIQR uses
21 NRS questions to evaluate the same three domains as
the FIQ (physical function, overall impact, and symptoms)
but diﬀers from the FIQ by having modiﬁed physical
function questions and the inclusion of questions on mem-
ory, tenderness, balance, and environmental sensitivity. The
NRS structure of the FIQR questions simplify scoring and
calculation of the subset domain and global scores. As in
the FIQ, the FIQR yields a 0-to-100 score with higher scores
indicating more severe FM. The FIQR has comparable scor-
ingcharacteristicstotheoriginalFIQ,makingcomparisonof
resultsbetweentheFIQandtheFIQRpossible.TheFIQRhas
the added functionality of computer-based administration,
and there is a disease-neutral version of the FIQR, the
SIQR, that can be used in population studies to identify and
study FM patients who have not been previously diagnosed
[53]. For these reasons, the FIQR is the recommended




of patients [2]. Since disturbed sleep can worsen numerous
other FM symptoms including pain, depression, and phys-
ical disability [2], accurately assessing sleep dysfunction is
vital. Three sleep assessments have been used in FM trials
(Table 2); the MOS sleep scale [54], the functional outcomes
of sleep questionnaire (FOSQ) [55], and the jenkins sleep
scale (JSS) [56]. All three scales are available in numerous
languages, allowing for their use in international FM studies.
The MOS Sleep Scale is a 12-item questionnaire designed
to evaluate key sleep domains by assessing sleep latency (2
items), duration, quality (4 items), snoring, awakening short
of breath or with headache, and daytime somnolence (3
items) over the past month [54]o rw e e k[ 57]. All items are
answered on a 6-point Likert scale from 1 = “all of the time”
to 6 = “none of the time” except for the time to sleep and
number of hours of sleep questions which are answered in
minutes and hours, respectively. Seven subscales are derived
to evaluate sleep disturbance, snoring, shortness of breath
or headache, adequacy, somnolence, quantity, and optimal
sleep. A sleep problems index can also be calculated from
9 of the items to generate a 0 to 100 score that quantiﬁes
overall sleep problems with higher scores indicating worse
sleep problems. As previously discussed, an analysis of FM
assessment measures showed the MOS sleep scale lacked
construct validity to assess change in sleep symptoms in FM
treatment trials [13]. This was because the MOS Sleep Scale
evaluates numerous problems, such as snoring and shortness
of breath, that are not relevant to many FM patients. The
analysis concluded that the sleep disturbance subscale may
be useful in isolation, but the MOS sleep scale as a whole
was not recommended for use in FM patients. Another
evaluation of the MOS sleep scale provided some evidence
for content validity in FM, but modiﬁcations to the scale
were recommended to improve the psychometric properties
and relevance in FM patients [58]. Based on these analyses
and the availability of other sleep questionnaires, the MOS
sleep scale is not recommended for quantifying the severity
of sleep symptoms in FM patients.
The FOSQ is a 30-item self-report questionnaire de-
signed to measure the impact of daytime sleepiness on
activities of daily living in people with sleep disorders using
functional status categories including general productivity,
activity level, vigilance, social outcomes, and intimacy and
sexual relationships [55]. Each item queries level of diﬃculty
withanactivityduetobeing“sleepyortired”andisanswered
from 1 = “yes, extreme (diﬃc u l t y ) ”t o4= “no (diﬃculty).”
FOSQ scores range from 5 to 20 with lower values indicating
worsefunctioning.TheFOSQwasdevelopedinpatientswith
disorders of excessive sleepiness, primarily obstructive sleep
apnea, recruited from university sleep disorder clinics [55].
The FOSQ has never been validated in FM patients. This
is signiﬁcant, as the FOSQ instructions state that “when
the words “sleepy” or “tired” are used, it describes the
feeling that you cannot keep your eyes open, your head is
droopy, you want to nod oﬀ, or you feel the urge to nap.
These words do not refer to the tired or fatigued feeling
you may have after you exercised.” FM patients commonly
have severe worsening of fatigue after exercise not seen in
typical patients that is likely to signiﬁcantly interfere with
their ability to correctly complete the questionnaire. For this
reason, the FOSQ cannot be recommended until validation
and reliability studies are completed in FM patients.
The JSS is a 4-item self-report questionnaire designed to
measure how often a subject has experienced sleep problems
in the past month [56]. JSS items evaluate trouble falling
asleep, staying asleep, waking up several times, and awaken-
ing unrefreshed with each item scored on a 5-point Likert
scale from 0 = “not at all” to 5 = “22–31 days.” Scores vary
from 0 to 20 with higher scores indicating more frequent
sleep problems. The JSS has been studied in FM patients and
found to be valid, reliable, and able to detect change after
treatment [59]. Of the three sleep questionnaires that have
been used in phase III FM trials, the JSS is recommended
for assessment of sleep symptoms in FM patients (Table 1).
However, the JSS has been criticized for possible high-recall
bias because it requires patients to rate frequency over the
pastmonth.Tolimitrecallbias,analternativescoringscheme
hasbeenproposedandprovisionallyvalidatedinFMpatients
by scoring each item either “not at all,” “less than 1/2 the
time,” or “greater than 1/2 the time” [59]. However, further
testingofthisalternatescoringschemeisneededbeforeitcan
be recommended for use in assessing FM patients.
13. Tenderness Assessments
Tenderness is a deﬁning feature of FM patients, deﬁned by
the 1990 ACR criteria as pain upon palpation at standard
tender point sites with 4kg/cm2 of force [3]. However,
decreases in the number of tender points have been shown to
correlate poorly with patient improvement in FM treatment
trials [52, 60]. This is likely because tender point counts do
not speciﬁcally measure tenderness but are a more general8 Pain Research and Treatment
measure of distress inﬂuenced by cognitive and emotional
aspects of pain perception [61, 62].
Change in the severity of pain at tender point sites has
been shown to be a better measure of tenderness than change
in the number of tender points. The manual tender point
survey (MTPS) is a standardized approach to performing the
tender point exam in which FM patients rate pain severity
upon digital palpation of each tender point on a verbal 11
point NRS [10]. Pain severity ratings from the 18 tender
points are averaged to yield a Fibromyalgia Intensity Score
(FIS) that varies from 0 to 10 with higher scores indicating
more severe tenderness. The MTPS/FIS has been used in a
pregabalin FM treatment trial, and decreases in FIS scores
with treatment were seen [63]. The tender point index (TPI)
is a similar tenderness measure to the FIS that supports its
use [3]. For the TPI, patients are asked to rate pain on a
0 to 4 scale upon digital palpation of each of the standard
18 FM tender points, and pain scores for all tender points
are summed to yield a 0 to 72 score with higher scores
indicating more severe tenderness. Signiﬁcant decreases in
TPI scores with active treatment compared to placebo were
demonstrated in a small milnacipran FM trial [64], but no
other trials have used the TPI.
While newer assessments currently under development
may prove superior for evaluating tenderness, such as the
multiple random staircase-evoked pain measure [60], they
remain unproven. The MTPS/FIS is the currently recom-
mended tenderness assessment for FM trials since it is stand-
ardized, can be performed with minimal training, and does
not require specialized equipment.
14. Recommended Evaluationsand
the PROMIS of FutureAssessments
As previously discussed, it is currently challenging to com-
pare results across diﬀerent treatment trials since diﬀerent
measurement tools are commonly used that often have
noncomparable or noncombinable scores. This limitation of
clinical trials is well known and not exclusive to FM. Two
routes have been taken to solve this problem: (1) require
a standard set of existing assessment tools to be used in
treatment trials or (2) develop a new set of assessment tools
for use in clinical trials. While groups like IMMPACT have
taken the ﬁrst route and made recommendations for the use
of existing assessment tools [15], these recommendations
have typically not been followed because regulatory bodies
like the US Food and Drug Administration have not made
themmandatory.Thisislikelyduetothefactthat,aswehave
seen in the case of FM, assessments that work well for one
condition do not work well for others. Because of this, the
FDA would need to develop a diﬀerent set of recommended
assessments for use in treatment trials of every condition.
The US National Institutes of Health roadmap project
Patient-Reported Outcomes and Measurement Information
System (PROMIS) has taken the second route to address
the need for uniform assessment measures in clinical trials.
PROMIS is a 5-year cooperative group program of research
designed to develop, validate, and standardize item banks to
measurepatient-reported outcomesrelevantacrosscommon
medical conditions [65]. The PROMIS network is working
to combine items from the best of all current patient self-
report questionnaires to create a set of standard symptom
severity assessments for use in clinical trials. In addition to
improving the ability to compare results from one trial to
another, use of PROMIS is expected to reduce the sample
size requirements of trials needed to demonstrate minimal
clinically important diﬀerences by 20% to 50%. PROMIS
also has great potential in clinical practice to rapidly and
reliably assess response to interventions and to inform treat-
ment decisions. PROMIS is particularly well suited for use
in FM treatment trials, as assessments have been developed
for all core FM symptom domains [66], and ﬁeld testing
of PROMIS item banks in >3500 FM patients is nearing
completion(privatecommunicationwithDavidA.Williams,
University of Michigan, Ann Arbor, Mh, USA). Assuming
PROMISitembanksareshowntobevalidandreliableinFM
patients, they will be the recommended assessment standard
for core FM symptom domains in addition to the FIQR and
PGIC for global improvement.
While PROMIS is being developed, the athens insomnia
scale (AIS) should be studied for use in assessing sleep
disturbance in FM patients [67]. The AIS is a recently devel-
oped 8-item self-report sleep questionnaire based on ICD-
10 insomnia diagnostic criteria that has been recommended
for use in therapeutic trials based on its superior feasibility,
validity, and psychometric properties compared to 44 other
sleep questionnaires including those discussed above [68].
The AIS cannot only quantify the severity of sleep problems
butalsobeusedtodiagnosepatientswithinsomnia[67].The
AIShasa5-itemsubscale,theAIS-5,thatisaunidimensional
measure of nighttime sleep problems similar to the JSS, and
scores on the two scales are highly correlated [67]. However,
the AIS is superior to the JSS since it also has 3 items that
measure the severity of daytime symptoms related to poor
sleep that are lacking in the JSS, and assessing the severity of
daytime symptoms is important to evaluate in patients with
sleep problems. However, recommendation of the AIS must
await validation and reliability testing in FM patients.
High ceiling eﬀects are typically seen when assessments
are used to quantify symptom severity in FM patients. As an
example, the ceiling eﬀect on the JSS total score was found
to be 27% in an FM treatment trial [59]. Assessments with
high ceiling eﬀects are problematic because they limit the
ability to adequately evaluate patients with severe symptoms
and measure symptom worsening (e.g., an FM patient
with a maximal JSS score at baseline is treated and, even
though their sleep symptoms worsen, the JSS score remains
unchanged from baseline which is wrongly interpreted as no
change in symptom severity). Patient impression of change
scales have been shown to be superior to other questionnaire
types in evaluating change in patients with severe symptoms
[69]. The FIBRO Change Scale have been proposed as a
way to use patient impression of change scales to better
evaluate change in FM patient symptoms in response to
therapy [70]. The FIBRO change scale includes seven patient
impressions of change scales to assess key FM symptoms
including fatigue, ﬁbrofog, sleep dysfunction, depression,Pain Research and Treatment 9
anxiety, stiﬀness, and pain each answered on a 0 to 10 scale
from 0 = “very much improved,” 5 = “no change” and
10 = “very much worse.” A similar scale could be developed
incorporating patient impression of change items for all 9
core FM symptom domains that could reduce the problem
of questionnaire ﬂoor and ceiling eﬀects in biomarker
development and therapeutic eﬃcacy evaluations. However,
such a scale will require validation studies in FM patients
before it can be recommended.
15. Conclusions
Objective biomarkers and new treatments are needed to
improve the diagnosis and management of FM. However,
research standards for FM clinical diagnosis and core FM
symptom domain assessments are needed to enable devel-
opment of biomarkers and new treatments. Since standards
for FM diagnosis and symptom assessment do not exist,
these recommendations are intended as a starting point for
discussions that will lead to the development of standards.
While none of the assessments discussed herein are perfect,
consensus within the FM research community must be
reached if timely advances for improving patient care are to
be made. The 1990 ACR FM classiﬁcation criteria performed
using the manual tender point survey (MTPS) standardized
method incorporating the ﬁbromyalgia intensity score (FIS)
is the recommended method for clinical diagnosis since
the 1990 criteria are well established, and the method
can be performed without any specialized equipment. Rec-
ommended assessments for core FM symptom domains
include the brief pain inventory average pain visual analogue
scale for pain intensity, the physical function subscale from
the revised ﬁbromyalgia impact questionnaire (FIQR) for
physical function, the patient global impression of change
(PGIC) and FIQR for overall/global improvement, the de-
pression subscale of the hospital anxiety and depression
scale (HADS-D) for depression, the multiple ability self-
report questionnaire (MASQ) for cognitive dysfunction, the
fatigue severity scale (FSS) for fatigue, the FIQR for multidi-
mensional function/health-related quality of life, the Jenkins
Sleep Scale (JSS) for sleep disturbance, and the MTPS-
FIS for tenderness. It is hoped that these recommendations
will provide an impetus for the development of universally
accepted standards of FM clinical diagnosis and symptom
domain assessments that can provide the foundation for
the development of objective FM biomarkers and new more
eﬀective treatment regimens.
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